Tag: VAX-31

Vaxcyte’s VAX-31 met all prespecified primary endpoints in the Phase 3 OPUS-1 trial, supporting its potential as a broader adult pneumococcal vaccine. The candidate includes all 20 Prevnar 20 serotypes plus 11 additional serotypes.